Veracyte

Champions Oncology has appointed Rob Brainin as Chief Executive Officer effective August 25, 2025, succeeding Dr. Ronnie Morris who will transition to Executive Chair.

Gustave Roussy has initiated UMBRELLA, a groundbreaking phase III trial that personalizes post-treatment cancer monitoring based on minimal residual disease (MRD) detected through blood-based circulating tumor DNA analysis.

Veracyte has launched the Decipher Prostate Metastatic Genomic Classifier, making it the only gene expression test covered by Medicare across all prostate cancer risk levels.

New data from the TOMBOLA trial demonstrates Veracyte's whole-genome sequencing-based MRD testing platform detected muscle-invasive bladder cancer with higher specificity than ddPCR-based methods.

• Bio-Rad Laboratories has entered a binding agreement to acquire Stilla Technologies, enhancing its digital PCR capabilities with Stilla's next-generation systems for applications including oncology diagnostics and infectious disease testing. • The acquisition, expected to close by Q3 2025, aims to serve the full spectrum of digital PCR applications and strengthen Bio-Rad's position in the rapidly growing global digital PCR market, projected to reach $3.68 billion by 2032. • Despite a recent 9.5% stock decline following the announcement, analysts remain optimistic about Bio-Rad's growth potential, with consensus estimates indicating a 12.2% earnings increase for fiscal 2025.

Relugolix plus radiotherapy demonstrates safety and efficacy for localized and advanced prostate cancer, offering a potential new treatment approach.

Veracyte's Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer in African American men, according to the VANDAAM trial.